- Home
- ALUR vs NXL Comparison
ALUR vs NXL Comparison
Compare ALUR & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALUR
- NXL
- Stock Information
- Founded
- ALUR 2009
- NXL 2010
- Country
- ALUR United States
- NXL United States
- Employees
- ALUR N/A
- NXL N/A
- Industry
- ALUR
- NXL Medical Specialities
- Sector
- ALUR
- NXL Health Care
- Exchange
- ALUR Nasdaq
- NXL Nasdaq
- Market Cap
- ALUR 16.8M
- NXL 14.0M
- IPO Year
- ALUR N/A
- NXL 2022
- Fundamental
- Price
- ALUR $2.17
- NXL $0.85
- Analyst Decision
- ALUR Strong Buy
- NXL Strong Buy
- Analyst Count
- ALUR 3
- NXL 1
- Target Price
- ALUR $22.83
- NXL $5.00
- AVG Volume (30 Days)
- ALUR 50.9K
- NXL 2.9M
- Earning Date
- ALUR 11-12-2025
- NXL 11-07-2025
- Dividend Yield
- ALUR N/A
- NXL N/A
- EPS Growth
- ALUR N/A
- NXL N/A
- EPS
- ALUR N/A
- NXL N/A
- Revenue
- ALUR $19,917,000.00
- NXL $174,813.00
- Revenue This Year
- ALUR N/A
- NXL $38.28
- Revenue Next Year
- ALUR $168.27
- NXL $185.71
- P/E Ratio
- ALUR N/A
- NXL N/A
- Revenue Growth
- ALUR N/A
- NXL 16.42
- 52 Week Low
- ALUR $1.98
- NXL $0.59
- 52 Week High
- ALUR $20.00
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- ALUR 41.79
- NXL 46.92
- Support Level
- ALUR $2.10
- NXL $0.79
- Resistance Level
- ALUR $2.23
- NXL $0.99
- Average True Range (ATR)
- ALUR 0.11
- NXL 0.08
- MACD
- ALUR 0.02
- NXL 0.01
- Stochastic Oscillator
- ALUR 51.85
- NXL 32.38
About ALUR Allurion Technologies Inc.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.